Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM4I02O)

Drug Name

NJA-730 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Graft-versus-host disease	4B24	Phase 1	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting CD40 messenger RNA (CD40 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ISIS 19213	DMD1JVZ	Discovery agent	N.A.	Investigative	[2]
ISIS 19211	DMKFCD5	Discovery agent	N.A.	Investigative	[2]
ISIS 19220	DMIKEXD	Discovery agent	N.A.	Investigative	[2]
ISIS 19219	DMFAWGX	Discovery agent	N.A.	Investigative	[2]
ISIS 19221	DMKOFNX	Discovery agent	N.A.	Investigative	[2]
ISIS 19218	DMX4I5A	Discovery agent	N.A.	Investigative	[2]
ISIS 19217	DMQK0AL	Discovery agent	N.A.	Investigative	[2]
ISIS 19212	DMLQT5F	Discovery agent	N.A.	Investigative	[2]
------------------------------------------------------------------------------------


⏷ Show the Full List of 8 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	Clinical pipeline report, company report or official report of NapaJen Pharma.
2	US patent application no. 6,197,584, Antisense modulation of CD40 expression.